Royalty Pharma (RPRX) P/E ratio

P/E ratio today
44.9×

Royalty Pharma (RPRX) trades at 44.9× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 21.7×. That is 23.1% higher than the 17.6× of fiscal 2024. Figures as of 18 Nov 2026, 07:08 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/E ratio today
44.9×
P/E ratio, fiscal 2025
21.7×
Change on fiscal 2024
+23.1%
Highest on record
395.2×fiscal 2022
Lowest on record
11.1×fiscal 2023
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Royalty Pharma P/E ratio, in more detail

Today's figure is 106.8% above the fiscal 2025 year-end.

Across the 6 fiscal year-ends on record (2020–2025), the highest was 395.2× in fiscal 2022 and the lowest 11.1× in fiscal 2023. Today's P/E ratio is higher than at 83% of the 6 fiscal year-ends on record; their median is 24.2×.

History · 6 fiscal years

P/E ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Royalty Pharma P/E ratio, year by year

Royalty Pharma (RPRX) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
Today44.9×—$68.68—
202521.7× 23.1% up$38.64$1.78
202417.6× 58.9% up$25.51$1.45
202311.1× 97.2% down$28.09$2.53
2022395.2× 1,377.7% up$39.52$0.10
202126.7× 29.5% down$39.85$1.49
202037.9×—$50.05$1.32

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

P/E ratio at health care companies of similar size

P/E ratio of Royalty Pharma and comparable companies
CompanyP/E ratio
IQVIA Holdings IQV31.3×
Royalty Pharma RPRX44.9×
Biogen BIIB108.6×

Price over the last twelve months' earnings per share, as the market data feed reports it.

More on RPRX

Royalty Pharma, figure by figure

Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value

Royalty Pharma P/E ratio: questions and answers

What is Royalty Pharma's P/E ratio?

Royalty Pharma (RPRX) trades at 44.9× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 21.7×. That is 23.1% higher than the 17.6× of fiscal 2024.

Is Royalty Pharma's P/E ratio high or low compared with its own history?

Today's P/E ratio is higher than at 83% of the 6 fiscal year-ends on record; their median is 24.2×.

What are the highest and lowest P/E ratio figures on record for Royalty Pharma?

Across the 6 fiscal year-ends on record (2020–2025), the highest was 395.2× in fiscal 2022 and the lowest 11.1× in fiscal 2023.

How is Royalty Pharma's P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Royalty Pharma (RPRX) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RPRX/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.